MicroRNAs, or miRNAs, are small molecules naturally present in the body that help regulate gene activity. Some circulate in the bloodstream, where their patterns can provide information about biological processes.

miRNAcX is a molecular analysis capability within ClinicOS AI Prevention. It uses AI to analyze serum microRNA profiles and present structured predictions for healthcare professionals to review alongside clinical information.

The analysis uses a serum microRNA profile obtained from a blood sample. Laboratory measurement produces the molecular data that miRNAcX analyzes.

The model includes 13 categories: gastric cancer, biliary tract cancer, colorectal cancer, lung cancer, bladder cancer, hepatocellular cancer, prostate cancer, pancreatic cancer, ovarian cancer, esophageal squamous cell cancer, breast cancer, bone and soft tissue sarcomas, and a noncancer group.

The report presents the predicted category, its model probability, and input quality information. It can also show other categories ranked by model probability to support professional interpretation.

It means the model assigned a probability of 99.4% to that category for the analyzed profile. It does not mean the patient has a 99.4% chance of having cancer, and it is not a measure of the system’s overall accuracy.

No. A prediction identifies the category favored by the model. A healthcare professional must interpret it alongside medical history and other clinical findings, with further evaluation where appropriate.

No. It means the model favored the noncancer category for that profile. It does not exclude cancer or replace appropriate clinical assessment and screening.

It indicates that the input data passed the quality checks reported by the system. It does not confirm that the prediction is correct or describe the patient’s health status.

Contact the DXP team to arrange a demonstration, review a sample report, and discuss the intended use and workflow requirements within ClinicOS AI Prevention.